Skip to main content
. 2015 Jun 5;5:11030. doi: 10.1038/srep11030

Figure 3. Survival benefit from VT requires Tie2.

Figure 3

(a) CD1 mice were infected with influenza virus (X31) and given placebo or daily 500 ng VT starting 48 hours after infection; *p < 0.05. Numbers in parentheses indicate the number of mice per group. (b)Tie2+/− (bred on a CD1 background) mice were infected with influenza virus (X31) and given placebo or daily VT starting 48 hours after infection, p = 0.18. (c) Arterial oxygen saturation was measured 5 days after infection in CD1 and Tie2+/− mice infected with influenza virus and administered VT, ***p < 0.001. (d) Body temperature measured 5 days after infection; *p < 0.05.